The Department of Veterans Affairs announced Aug. 5 it is launching the first psilocybin clinical trial in VA history, evaluating the Schedule I compound as a treatment for major depression in veterans, including those with concurrent post-traumatic stress disorder.
The trial marks a major shift in the federal government’s largest health care system and could signal a broader rethinking of restrictions on psychedelic compounds for medical research purposes.
Psilocybin, the active compound in so-called magic mushrooms, remains a Schedule I controlled substance under federal law, a classification reserved for drugs with no accepted medical use and high abuse potential. The VA trial proceeds under a Drug Enforcement Administration research registration and FDA Investigational New Drug authorization.
Veterans with treatment-resistant depression represent a significant portion of the VA’s mental health caseload. Standard treatments, including antidepressant medications and therapy, fail to adequately help a substantial number of veterans, leaving clinicians with limited options.
The psilocybin trial follows a separate VA clinical trial of semaglutide, a GLP-1 drug, for alcohol use disorder launched in recent weeks. Together, the studies reflect a broader expansion of VA clinical research into novel therapeutic approaches.
Research at academic institutions including Johns Hopkins University and New York University has shown promising results for psilocybin-assisted therapy in treating depression, anxiety, and PTSD, though large-scale clinical trials are still limited.
The VA operates the largest integrated health care system in the United States, serving more than 9 million enrolled veterans. Its entry into psilocybin research lends institutional credibility to a therapeutic area that has gained momentum in the scientific community.